Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma
Meningioma of Brain
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- Not specified - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 50 Actual
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma and associate its expression with certain clinical and pathological paramaters as age, sex of the patients, site (right or left and location), size, diagnosis, WHO grade, if there is bone invasion, if there is necrosis and vascular invasion.
Read the full description
Meningiomas are the most common primary central nervous system (CNS) tumors. Since the PHH3 was reported to be unique to mitosis, the anti-PHH3 antibody was being increasingly studied as a proliferation marker.
50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.
The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type and grade of each tumor.
Another sliced tissue sections will be immunohistochemically stained with PHH3 monoclonal antibodies and assess its expression by counting positive mitotic nuclei. Correlation of PHH3 proliferative index with WHO histological grade and other clinicopathological parameters.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
1\) Histologically confirmed meningioma cases. 2) Cases classified according to WHO CNS5 (2021). 3) Tissue blocks with sufficient material. 4) Specimens with sufficient clinical data.
\-
Exclusion Criteria:
1\) Tissue blocks with insufficient, destroyed or necrotic material. 2) Specimens with insufficient clinical data.
\-
Study population
Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Participants
Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Biological: Immunohistochemical staining
Immunohistochemical staining BIOLOGICAL
Immunohistochemical staining of paraffin embedded blocks of meningioma tissues by PHH3 monoclonal antibodies and assess its expression by counting positive mitotic nuclei. Correlation of PHH3 proliferative index with WHO histological grade and other clinicopathological parameters.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma.
Time frame: 6 months
PHH3 expression was evaluated by immunohistochemistry in meningioma specimens and scored according to the percentage of tumor cells showing positive nuclear staining. Expression was categorized into grade 1,2,3 for statistical analysis.
Secondary measures
Age
Time frame: 6 months
Assessment of the association between PHH3 immunohistochemical expression and age subgroups
Sex
Time frame: 6 months
Assessment of the association between PHH3 immunohistochemical expression and sex
Tumor site
Time frame: 6 months
Assessment of the association between PHH3 immunohistochemical expression and tumor site
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Faculty of medicine Sohag universitySohag, EgyptStatus unknown
Study team and timeline
- Lead sponsor
- Sohag University
- Study start
- Sep 1, 2026 Actual
- Primary completion
- Oct 1, 2026 Actual
- Study completion
- Oct 22, 2026 Actual
- First posted
- Nov 9, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
No central contact is listed. Check the locations and the official record.
Official study title
Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026